Canakinumab (an interleukin 1β inhibitor) is a breakthrough in the possibilities of anti-inflammatory therapy for gout
Main Authors: | , , |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA PRESS LLC
2013-11-01
|
Series: | Научно-практическая ревматология |
Online Access: | https://rsp.mediar-press.net/rsp/article/view/1156 |